沃森生物被责令改正 三季末易方达招商基金为流通股东

Core Viewpoint - Yunnan Watson Bio (300142) has been ordered to rectify its governance practices due to non-compliance with regulations regarding the approval of director and senior management remuneration for 2023 and 2024 [1][3][4] Group 1: Regulatory Violations - The company failed to submit the remuneration matters for directors to the shareholders' meeting for approval as required by the Corporate Governance Guidelines [1][3] - Senior management remuneration matters were not submitted to the board for approval, violating the same governance standards [1][3] Group 2: Regulatory Actions - The Yunnan Securities Regulatory Bureau has decided to impose corrective administrative measures on Watson Bio, which will be recorded in the securities and futures market integrity archives [1][4] - The company is required to take effective measures to rectify the situation within 30 days of receiving the decision and submit a written report on the rectification [4] Group 3: Shareholder Information - As of September 30, 2025, the largest shareholder is the Industrial and Commercial Bank of China - E Fund ChiNext ETF, holding 34,471,370 shares (2.16%) [2] - The ninth largest shareholder is the Bank of China - CICC National Bio-Medical Index Fund, holding 23,067,800 shares (1.44%) [2]